Biomarkers /

HIST2H3C

Back to Biomarkers List

Overview

Location [1]
1q21.2
Synonyms [1]
H3/M, H3FN, H3.2, H3FM, H3, H3F2

HIST2H3C is altered in 1.00% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, invasive breast carcinoma, and unknown having the greatest prevalence of alterations [3].

HIST2H3C GENIE Cases - Top Diseases

The most common alterations in HIST2H3C are HIST2H3C Amplification (1.00%) and HIST2H3C Loss (0.01%) [3].

HIST2H3C GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.